Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 161

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 161
---
, 2023, as part of our cooperation agreement with SciSparc. The invention disclosed therein is directed to compositions and methods for potentiating therapeutic effects and/or reducing side-effects of lysergic acid diethylamide (LSD). The patent application provides pharmaceutical compositions and combinations comprising LSD and N-acylethanolamines, and methods for their use in a variety of indications amenable to treatment, including, but not limited to, depression, anxiety, headaches, alcoholism, and pain. 97 Compositions comprising KETAMINE and N-acylethanolamines and uses thereof is a patent family filed on February 15, 2023, as part of our cooperation agreement with SciSparc. The patent application relates to compositions and methods for potentiating therapeutic effects and/or reducing side-effects of ketamine. The patent application provides pharmaceutical compositions and combinations comprising ketamine and N-acylethanolamines, for example, Palmitoylethanolamide (“PEA”) and methods for their use in a variety of indications amenable to treatment, including, but not limited to depression, suicidal ideation, bipolar disorder, seizures, and pain. Compositions comprising IBOGAINE and N-acylethanolamines and uses thereof is a patent family filed on February 15, 2023, as part of our cooperation agreement with SciSparc. The patent application relates to compositions and methods for potentiating therapeutic effects and/or reducing side-effects of ibogaine. The patent application provides pharmaceutical compositions and combinations comprising ibogaine and N-acylethanolamines for example, Palmitoylethanolamide (“PEA”) and methods for their use in a variety of indications amenable to treatment, including, but not limited to substance addiction and opioid dependence. Compositions comprising PSILOCYBIN and N-acylethanolamines and uses thereof is a patent family filed on February 10, 2023, as part of our cooperation agreement with SciSparc. The patent application relates to compositions and methods for potentiating therapeutic effects and/or reducing side-effects of psilocybin. The patent application provides pharmaceutical compositions and combinations comprising psilocybin and N-acylethanolamines, for example, Palmitoylethanolamide (“PEA”) and methods for their use in a variety of indications amenable to treatment, including, but not limited to substance addiction and dependence. Compositions comprising N,N-DIMETHYLTRYPTAMINE and N-acyle